POINT Biopharma Global Inc.

PNTNASDAQHealthcare

$12.50

+$0.02(+0.16%)

Market Cap$1.3B

P/E Ratio—

52W High$14.35

52W Low$6.57

Avg Volume3.2M

Open$12.50

Beta-0.00

Overview

POINT Biopharma Global Inc.（PNT）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

pnt · 股价预测 · 12 位分析师（近3月）· FMP · 更新于 2025年4月11日

分析师评级与共识

基于过去 3 个月内 12 位华尔街分析师

Buy

12 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 12 · 买入占比: 58.3%

12 个月目标价

High

$17.00

Consensus

$13.75

+10.0% upside

Low

$10.00

Median: $14 · Last Close: $12.50

POINT Biopharma Global Inc.（PNT）的分析师共识为 Buy，基于过去 3 个月内 12 位华尔街分析师的评级。PNT 的 12 个月平均目标价为 $13.75，相对当前价 $12.50 代表 +10.0% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $14 (10.0%)High $17Low $10

Consensus Target

$13.75

10.0% upside

High Target

$17

36.0%

Low Target

$10

-20.0%

Current Price

$12.50

as of today

Based on analyst price targets, the PNT stock price prediction for the next 12 months ranges from $10 to $17. The consensus PNT price forecast of $13.75 implies 10.0% upside from the current price of $12.50.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-10	$12.03	↓ 3.77%	$11.98	$12.08

1-day model range: $11.98–$12.08. Peak: $12.08 (-3.77%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

14%29%57%

2Buy

4Neutral

8Sell

RSI (14)21.3Oversold

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · PNT · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$12.50BUY

MA 10$12.63SELL

MA 20$13.28SELL

MA 50$13.21SELL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $PNT · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$12.53SELL

EMA 10$12.73SELL

EMA 20$13.01SELL

EMA 50$12.99SELL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $PNT · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2023-10-24	Piper Sandler	Downgrade ↓	Overweight→Neutral
2023-10-06	Raymond James	Downgrade ↓	Outperform→Market Perform
2023-10-05	Raymond James	Downgrade ↓	Outperform→Market Perform
2023-10-04	Truist Securities	Downgrade ↓	Buy→Hold
2023-10-04	JonesTrading	Downgrade ↓	Buy→Hold
2023-10-03	Truist Securities	Downgrade ↓	Buy→Hold
2023-10-03	JonesTrading	Downgrade ↓	Buy→Hold
2023-05-16	Oppenheimer	Maintains	Outperform→Outperform
2023-05-15	Oppenheimer	Maintains	Outperform→Outperform
2022-12-14	Raymond James	Maintains	Outperform→Outperform

Piper Sandler2023-10-24

Downgrade ↓

Overweight→Neutral

Raymond James2023-10-06

Downgrade ↓

Outperform→Market Perform

Raymond James2023-10-05

Downgrade ↓

Outperform→Market Perform

Truist Securities2023-10-04

Downgrade ↓

Buy→Hold

JonesTrading2023-10-04

Downgrade ↓

Buy→Hold

Truist Securities2023-10-03

Downgrade ↓

Buy→Hold

JonesTrading2023-10-03

Downgrade ↓

Buy→Hold

Oppenheimer2023-05-16

Maintains

Outperform→Outperform

Oppenheimer2023-05-15

Maintains

Outperform→Outperform

Raymond James2022-12-14

Maintains

Outperform→Outperform

Wall Street analysts have recently issued updated ratings on POINT Biopharma Global Inc. (PNT) stock. Of the recent 25 rating actions, 2 were upgrades and 7 were downgrades. 12 analysts currently cover PNT.

分析师推荐趋势

Buy ratings3 → 0↓ 3

Hold ratings0 → 7↑ +7

Sell ratings0 → 0

PNT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$241M

↑ 66.7% YoY

Revenue Next Year

$17M

↓ 93.1% YoY

EPS This Year

$0.95

EPS Next Year

$-1.12

↓ 217.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PNT EPS of $0.95 for the current fiscal year, based on estimates from 5 analysts. The PNT revenue forecast is $241M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

PNT 股价预测由两类独立数据源支撑：来自 12 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PNT 的共识目标价为 $13.75（+10.0% 上行空间），分析师共识为 Buy。

PNT 的短期预测（明日）为 $12.03（-3.77%）。

POINT Biopharma Global Inc. 在 NASDAQ 上市，代码 PNT。PNT 在 2027 年的整体展望偏积极，在覆盖分析师中约 58% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

PNT 预测 · 8 个问题

根据 12 位华尔街分析师，PNT 的 12 个月平均目标价为 $13.75，最高 $17.00、最低 $10.00。若有图表，中位目标价可在上方查看。相对当前价 $12.50，隐含约 +10.0% 的上行空间。

PNT 目标价PNT 分析师目标价PNT 12个月目标价目标价 PNT

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.